Eli Lilly to bring experimental weight-loss pill in India

MUMBAI, Sept 25 (Reuters): Eli Lilly plans to launch its experimental oral weight-loss drug orforglipron in India, a senior executive said on Thursday, offering an alternative to injectables that many patients in the world's most populous nation resist.
Orforglipron is part of a new class of GLP-1 drugs that suppress appetite and follow the same pathway targeted by Eli Lilly's blockbuster tirzepatide, sold globally as the blockbuster Mounjaro for diabetes and Zepbound for weight loss.
The drug has not been launched anywhere globally but Lilly plans to file
, opens new tab for approval of orforglipron with regulators in the United States, Britain, European Union, Japan and China.
It was not immediately clear if the drugmaker has started approval procedure for orforglipron in India.
Latest trial data showed Eli Lilly's experimental pill orforglipron lowered blood sugar and weight more effectively.